All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2021; the latest 2024-11-29.
From the record
Embecta Corp.'s filings since 2021 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-11-29) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-0.1% a year over 6 filed years; profitable in 6 of 6.
From the record
Embecta Corp.'s 6 filed years say what it did: revenue went from $1.1 billion in fiscal 2020 to $1.1 billion in fiscal 2025, down 0.1% a year; it rose in 2 of 5 years; the deepest fall was 7% from fiscal 2021 to fiscal 2025; net income was positive in 6 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 0.8% a year. 35% of cash flow returned. Insiders: 1 sales, 4 purchases.
From the record
Over the 3 fiscal years to 2025-09-30, Embecta Corp.'s diluted share count grew about 0.8% a year, and dividends and buybacks returned about 35% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 1 sale and 4 purchases of their own stock on the open market in the year to 2026-09-30, buying about $558 thousand (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
Leverage 160%: owes 160¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-09-30, Embecta Corp.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 62 cents per dollar of everything the company owns. Leverage: it owed about 160 cents per dollar of assets, and net share issuance: its share count grew 1.0% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 39% of 109 in its family; net margin 8.8%.
From the record
Embecta Corp.'s standing among 109 graded names in its industry family: revenue of $1.1 billion in fiscal 2025 ranks in the top 18% by size; a net margin of 8.8% ranks in the top 20%; revenue growth of -1.5% a year over the last 3 filed years ranks in the bottom 21% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 8.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Embecta Corp.'s leadership is put at 8.3 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 17% of 108 in its family; the record of its people begins on 2022-02-10 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 4.8 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 39% of 104 in its family for room to expand.
From the record
Embecta Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $229 million against debt of $1.4 billion leaves -106.3% of its assets as net cash, bottom 1% of its family; cash from operations less capital spending is 16.9% of revenue (top 13%); a gross margin of 62.6% (top 45%); research spending of 3.5% of revenue (bottom 14%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 22% of 105 in its family for growth drivers.
From the record
Embecta Corp.'s growth drivers, from the filed years to fiscal 2025: revenue grew -1.5% a year over the last three filed years against -0.1% over all 6, slowing (bottom 44% of its family); the newest year grew -3.8% (bottom 18%); research spending grew -17.7% a year (bottom 7%); capital spending grew -26.7% a year (bottom 21%) (its annual reports). Embecta Corp. reported 5 product lines in fiscal 2025: Pen Needles at $784 million (73%), Safety at $138 million (13%), Syringes at $125 million (12%), and 2 more; 3 of 5 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 32% of 88 in its family for expectations against reality.
From the record
Embecta Corp.'s newest year against its own record: revenue of $1.1 billion in fiscal 2025 came in 3.5% below the $1.1 billion its prior three years' pace pointed to (bottom 48% of its family); net income of $95 million against a prior three-year average of $124 million (bottom 27%); a net margin of 8.8% against 11% before (bottom 22%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made